NewGenIvf Group Ltd (NIVF) — Titan Protect Analysis

NIVF

NewGenIvf Group Ltd

Healthcare · ·

$0.64

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3M

Total market value of the company

Trailing P/E

0.02

Very cheap relative to earnings

Forward P/E

0.10

Based on estimated future earnings — lower means cheaper

Rev Growth

+11.9%

Year-over-year revenue change

Profit Margin

209.0%

How much profit the company keeps from each dollar of revenue

ROE

79.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$900.00

+140966% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 1 analysts covering this stock

About NewGenIvf Group Ltd

NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing. It also offers I

https://www.nivf.global

Country: Thailand Employees: 87 Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.364

Positive but modest risk-adjusted returns

Kelly Fraction

0.0801

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

-0.986

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-98.6%

Historical annualised return based on price data

Max Drawdown

-100.0%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

232

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.03

Very low correlation to market moves

52W High

$1,067.70

100% below the year high

52W Low

$0.72

-11% above the year low

Avg Volume

2,310,534

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$36.48

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

18.74

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

20.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-349.1%

Profit from core operations before interest and tax

Free Cash Flow

$-10,464,332

Negative — the business is spending more than it generates

Revenue (TTM)

$5M

Total revenue over the last 12 months

Net Income

$10M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$900.00

Target Median

$900.00

Target Low

$900.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go